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1. THE STRATEGIC CHALLENGES 
Life sciences and biotechnology are widely recognised to be, after information 
technology, the next wave of the knowledge-based economy, creating new 
opportunities for our societies and economies.  
They also raise important policy and societal issues and have given rise to a broad 
public debate, as confirmed in the comprehensive public consultation carried out by 
the Commission during autumn 2001
1. These issues must be addressed with great 
care and sensitivity. In Europe, however, the relevant responsibilities fall across a 
broad range of policies and actors. In the absence of a shared vision of what is at 
stake and without common objectives and effective coordination, Europe has 
therefore only slowly and with difficulty addressed the challenges and opportunities 
of these new technologies. 
Our democratic societies should offer the necessary safeguards and channels of 
dialogue to ensure that the development and application of life sciences and 
biotechnology take place respecting the fundamental values recognised by the EU in 
the Charter of Fundamental Rights. 
Europe is faced with a major policy choice: either accept a passive and re-active role, 
and bear the implications of the development of these technologies elsewhere, or 
develop pro-active policies to exploit them in a responsible manner, consistent with 
European values and standards. The longer Europe hesitates, the less realistic this 
second option will be. 
The Community is competent on important policy aspects of relevance, and the 
Commission therefore has a particular responsibility to assist in finding ways 
forward. The present initiative proposes a framework for this.  
1.1.  Technology revolution and policy response 
A revolution is taking place in the knowledge base of life sciences and 
biotechnology, opening up new applications in health care, agriculture and food 
production, environmental protection, as well as new scientific discoveries. This is 
happening globally. The common knowledge base relating to living organisms and 
ecosystems is producing new scientific disciplines such as genomics and 
bioinformatics and novel applications, such as gene testing and regeneration of 
human organs or tissues. These in turn offer the prospect of applications with 
profound impacts throughout our societies and economies, far beyond uses such as 
genetically modified plant crops. 
The expansion of the knowledge base is accompanied by an unprecedented speed in 
transformation of frontier scientific inventions into practical use and products and 
                                                 
1  Commission Communication "Towards a Strategic Vision of Life Sciences and 
Biotechnology: Consultation Document", COM (2001) 454 of 4.9.2001. The 
Communication, public web-comments and results of a Commission Stakeholder Conference 
held 27-28 September 2001 are available at http://europa.eu.int/comm/biotechnology. 
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thus also represents a potential for new wealth creation: old industries are being 
regenerated and new enterprises are emerging, offering the kind of skill-based jobs 
that sustain knowledge-based economies. As probably the most promising of the 
frontier technologies, life sciences and biotechnology can provide a major 
contribution to achieve the European Community's Lisbon Summit’s objective of 
becoming a leading knowledge-based economy. The European Council in Stockholm 
in March 2001 confirmed this and invited the Commission, together with the 
Council, to examine measures required to utilise the full potential of biotechnology 
and strengthen the European biotechnology sector's competitiveness in order to 
match leading competitors while ensuring that those developments occur in a 
manner which is healthy and safe for consumers and the environment, and consistent 
with common fundamental values and ethical principles. 
Europe's current performance in life sciences and biotechnology is not facilitating the 
achievement of that objective.  
In Europe and elsewhere, intensive public debate has emerged. While the public 
debate has contributed to awareness and concrete improvements on important issues, 
it has also focused narrowly on genetically modified organisms (GMOs) and specific 
ethical questions, on which public opinion has become polarised. In the Community, 
like in other regions and countries, the scientific and technological progress in these 
areas raises difficult policy issues and complex regulatory challenges. Uncertainty 
about societal acceptance has contributed to detract attention in Europe for the 
factors that determine our capacity for innovation and technology development and 
uptake. This has stifled our competitive position, weakened our research capability 
and could limit our policy options in the longer term.  
Europe is currently at a crossroads: we need to actively develop responsible policies 
in a forward-looking and global perspective, or we will be confronted by policies 
shaped by others, in Europe and globally. The technology and its applications are 
developing rapidly – the Commission believes that Europe’s policy choice is, 
therefore, not whether, but how to deal with the challenges posed by the new 
knowledge and its applications. 
1.2.  A European Strategy 
The European Commission wishes to contribute actively to the reflection on these 
issues and to address the challenges. In September 2001, it launched a broad public 
consultation on the wide range of issues at stake
2. These issues can only in part be 
addressed by the Community - most depend on many other public and private actors. 
In some areas such as product approvals, safeguarding the internal market, 
agricultural and trade policies, the Community has exclusive competence. On other 
aspects, the Community has no competence or shares it with Member States. The 
ultimate responsibility for success or failure is therefore a shared one. 
But respecting the subsidiarity principle should not prevent Europeans from working 
together towards common goals. Within a shared vision of the long-term and global 
opportunities and challenges, we can develop clear strategic objectives and coherent 
and holistic approaches, relying also on new forms of collaboration and monitoring, 
                                                 
2  COM(2001) 454 of 4.9.2001 
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in particular through open coordination and benchmarking which underpins the 
Lisbon Strategy. 
With the present initiative, the European Commission proposes a strategy for 
Europe to develop sustainable and responsible policies to address the following three 
broad questions: 
•  Life sciences and biotechnology offer opportunities to address many of the 
global needs relating to health, ageing, food and the environment, and to 
sustainable development. How can Europe best attract the human, industrial and 
financial resources to develop and apply these technologies to meet society’s 
needs and increase its competitiveness? 
•  Broad  public support is essential, and ethical and societal implications and 
concerns must be addressed. How can Europe deliver effective, credible and 
responsible policies which enjoy the confidence and support of its citizens? 
•  The scientific and technological revolution is a global reality which creates new 
opportunities and challenges for all countries in the world, rich or poor. How can 
Europe best respond to the global challenges, develop its domestic policies with a 
clear international perspective and act internationally to pursue its interests? 
The Commission proposes a strategy to respond with responsible, science-based, and 
people-centred policies on an ethical basis. This strategy aims to allow Europe to 
benefit from the positive potential of life sciences and biotechnology (sections 2 and 
3), to ensure proper governance (section 4), and to meet Europe’s global 
responsibilities (section 5). This is a proposal for an integrated strategy – its different 
elements are interdependent and mutually reinforcing.  
Implementing this strategy requires an open, collaborative and sustained process to 
develop coherent and credible policies (section 6). The Commission also proposes an 
action plan for concrete measures by the Commission and the Community, as well 
as recommendations for other public and private actors, respecting the subsidiarity 
principle. 
2. THE POTENTIAL OF LIFE SCIENCES AND BIOTECHNOLOGY 
Life sciences and biotechnology are widely regarded as one of the most promising 
frontier technologies for the coming decades. Life sciences and biotechnology are 
enabling technologies - like information technology, they may be applied for a wide 
range of purposes for private and public benefits. On the basis of scientific 
breakthroughs in recent years, the explosion in the knowledge on living systems is 
set to deliver a continuous stream of new applications. 
There is a huge need in global health care for novel and innovative approaches to 
meet the needs of ageing populations and poor countries. There are still no known 
cures for half of the world’s diseases, and even existing cures such as antibiotics are 
becoming less effective due to resistance to treatments. Biotechnology already 
enables cheaper, safer and more ethical production of a growing number of 
traditional as well as new drugs and medical services (e.g. human growth hormone 
without risk of Creutzfeldt-Jacobs Disease, treatment for haemophiliacs with 
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unlimited sources of coagulation factors free from AIDS and hepatitis C virus, 
human insulin, and vaccines against hepatitis B and rabies). Biotechnology is behind 
the paradigm shift in disease management towards both personalised and preventive 
medicine based on genetic predisposition, targeted screening, diagnosis, and 
innovative drug treatments. Pharmacogenomics, which applies information about the 
human genome to drug design, discovery and development, will further support this 
radical change. Stem cell research and xenotransplantation offer the prospect of 
replacement tissues and organs to treat degenerative diseases and injury resulting 
from stroke, Altzheimer’s and Parkinson’s diseases, burns and spinal-cord injuries.  
In the agro-food area, biotechnology has the potential to deliver improved food 
quality and environmental benefits through agronomically improved crops. Since 
1998, the area cultivated with genetically modified (GM) crops world-wide has 
nearly doubled to reach some 50 million hectares in 2001 (in comparison with about 
12.000 hectares in Europe). Food and feed quality may be linked to disease 
prevention and reduced health risks. Foods with enhanced qualities (“functional 
foods”) are likely to become increasingly important as part of life-style and 
nutritional benefits. Plant genome analysis, supported by a FAIR research project, 
has already led to the genetic improvement of a traditional European cereal crop 
(called Spelt) with an increased protein yield (18%) which may be used as an 
alternative source of protein for animal feed
3. Considerable reductions in pesticide 
use have been recorded in crops with modified resistance. The enhancement of 
natural resistance to disease or stress in plants and animals can lead to reduced use of 
chemical pesticides, fertilisers and drugs, and increased use of conservation tillage - 
and hence more sustainable agricultural practices, reducing soil erosion and 
benefiting the environment. Life sciences and biotechnology are likely to be one of 
the important tools in fighting hunger and malnutrition and feeding an increasing 
human population on the currently cultivated land area, with reduced environmental 
impact. 
Biotechnology also has the potential to improve non-food uses of crops as sources 
of industrial feedstocks or new materials such as biodegradable plastics. Plant-based 
materials can provide both molecular building blocks and more complex molecules 
for the manufacturing, and energy and pharmaceutical industries. Modifications 
under development include alterations to carbohydrates, oils, fats and proteins, fibre 
and new polymer production. Under the appropriate economic and fiscal conditions, 
biomass could contribute to alternative energy with both liquid and solid biofuels 
such as biodiesel and bioethanol as well as processes such as bio-desulphurisation. 
Plant genomics also contributes to conventional improvements through the use of 
marker-assisted breeding. 
New ways to protect and improve the environment are offered by biotechnology 
including bioremediation of polluted air, soil, water and waste as well as 
development of cleaner industrial products and processes, e.g. based on use of 
enzymes (biocatalysis).  
                                                 
3  http://europa.eu.int/comm/research/agro/fair/en/be1569.html  
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3. HARVESTING THE POTENTIAL 
The potential of life sciences and biotechnology is being exploited at an accelerating 
rate and is likely to engender a new economy with creation of wealth and skilled 
jobs. Less certain is the time profile and orientations of this development and 
whether Europe will fully participate.  
Some estimates suggest that by the year 2005 the European biotechnology market 
could be worth over € 100 billion. By the end of the decade, global markets, 
including sectors where life sciences and biotechnology constitute a major portion of 
new technology applied, could amount to over € 2000 billion. 
 
 
Direct and indirect market potential of life sciences and biotechnology
1 
Industrial  €1500 bn market globally in 2010 in sustainable industrial and 
environmental technology (only partly biotech) with 
environmental technology estimated at €90-120 bn
2  
Pharmaceutical  €506 bn world market in 2004 (€818 bn in 2010 assuming 
constant increase)
 3  
Agricultural  Although there is a steady increase in area sown with genetically 
modified seeds, the future market value is difficult to predict, as 
it would depend on the possible development of a non-GM feed 
market. Million hectares world-wide
4: 
  1998 1999 2000  2001   
  28 40 44  53   
Allowing for the uncertainty of estimates from different sources, the above would 
imply that in 2010 there would be a total world market (excluding agriculture) of 
above 2.000 billion Euro in sectors where a major portion of the new technology and 
a substantial part of the total technology comes from biotechnology companies.
 
1  Beyond quoted figures, comparative data on international competitiveness in biotechnology are difficult to 
establish: The main value factor is knowledge, and the usual statistical data on turnover/sales/exports do not 
reveal the location where value in terms of intellectual property has been added 
2  UK gov. data: from DTI's Bio-Wise programme launched in 1999: OECD: POST Report 136, April 2000 
3  IMS Health, (www.imshealth.com) 
4  ISAAA: International Service for the Acquisition of Agri-Biotech Applications 
Europeans are also likely to become major beneficiaries of solutions offered by life 
sciences and biotechnology - in the form of products and services for consumers, for 
public benefits and throughout the production system. But to manage this 
development, to give us options, to project our values and policy choices 
internationally, and to reap the benefits of a new emerging economy, Europe should 
also command the knowledge base and its transformation into new products, 
processes and services.  
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3.1. The  knowledge-base 
The life sciences revolution was born in, and is fed and nurtured by, research. Public 
research laboratories and institutions of higher education are at the core of the 
science base interacting also with enterprise-based research and that of other private 
bodies. 
The success of any knowledge-based economy rests upon the generation, diffusion 
and application of new knowledge. Investments in research and development, 
education and training and new managerial approaches are therefore of key 
importance in meeting the challenges posed by life sciences and biotechnology. 
One of Europe’s main strengths is its science base; centres of scientific excellence in 
specific technologies exist and are at the core of regional clusters of biotechnology 
development. However, total European investment in R&D is lagging behind the US. 
Moreover, Europe suffers from fragmentation of public research support, and from 
the low level of interregional co-operation in R&D, among companies and 
institutions from different regions of several states. 
The Commission aims to restore European leadership in life sciences and 
biotechnology research. The 6
th Community Framework Programme for Research, 
Technological development and Demonstration activities (2002-2006) proposes this 
area as the first priority and will provide a solid platform for constructing, in 
collaboration with the Member States, a European Research Area. This should 
reinforce R&D capacity and help overcome existing fragmentation of research 
policies and efforts. When Europeans work together, maximising collaboration and 
minimising duplication, we can better meet major challenges such as the handling of 
the ever-increasing volumes of data and information and ensuring full participation 
in global scientific initiatives.  
Moreover, European research efforts should focus on the new prospects that are 
opening up through multi-disciplinary research. New discoveries are made most 
often in when biological research is carried out in conjunction with other sciences 
and disciplines such as information technology, chemistry and process engineering. 
For example, human genome analysis into so-called “gluten allergy” may ultimately 
lead to the development of allergen-reduced cereals. A first fully integrated 
Community project has recently been launched to ensure leadership at the genomes-
medicine interface where biotechnology is yielding innovative approaches to 
treatments of human and animal diseases. 
Europe’s research agenda for life sciences should be based on the needs of its 
citizens and attuned to our particular requirements. This calls for an approach which 
actively identifies the needs and opportunities presented by European societies and 
seeks to address them through innovative research. We need to further strengthen the 
links between research and other Community policies, including the scientific basis 
for health and safety regulations. In the same logic, it is also of utmost importance to 
involve scientists and researchers as closely as possible in societal consensus 
building. New research partnerships should also be encouraged amongst developed 
and developing nations to take full advantage of promising technologies and 
biodiversity potential, the basis for future progress. 
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3.2.  Europe’s capacity to offer scientific and technological solutions 
The potential for applications of life sciences and biotechnology promises to be a 
growing source of wealth creation in the future, leading to the creation of jobs, many 
of which will be highly skilled ones, and new opportunities for investment in further 
research.  
If Europe is to benefit from this, excellence in the science-base is not enough: it is 
essential to have the capacity to translate knowledge into new products, processes 
and services, that in turn will generate benefits to society, skilled jobs and prosperity. 
The development of new capacity involves the encouragement of the entire research 
and innovation process to attract and train researchers, to attract investment and 
resources, and to provide a balanced and responsible legal, regulatory and policy 
framework.  
During the 1980s, biotechnology in Europe developed primarily within large 
companies whereas, unlike the US, the small company sector remained mostly 
stagnant. While large companies in the pharmaceutical and chemical sectors continue 
to exploit the technology to provide innovative products, we have seen a rapid 
expansion of the small companies sector in Europe in the recent past. There are now 
more dedicated biotechnology companies in Europe (1570), than in the US (1273). 
This is an encouraging demonstration of entrepreneurial potential in Europe.  
Biotechnology Industry in Europe compared to the US
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Note: European data for 2000 and 2001 are adjusted by the inclusion of the Swiss biotech company Serono 
However, the European SMEs are relatively small companies, whereas the US 
biotechnology industry started earlier, produces more than three times the revenues 
of the European industry, employs many more people (162.000 against 61.000), is 
much more strongly capitalised and in particular has many more products in the 
pipeline. 
The Commission’s 2001 report on Competitiveness (Chapter V) analysed in detail 
why commercial development of EU industry currently lags behind that of the US in 
Transforming 
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the biotechnology sector. Intellectual property rights were identified as a relevant 
factor to be taken into account. 
Structurally, biotechnology SMEs are very capital-intensive, and investments have 
long payback periods. Risk capital funding has been increasingly available, but does 
not appear to be sufficient at all stages of the long company development process. 
Insufficient supply of skilled personnel may develop into a major constraint for 
industry development. 
Comparison of Employment
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Eliminating such bottlenecks is as important as fostering an entrepreneurial Europe 
with sufficient incentives for innovation and economic risk-taking to create the 
necessary dynamics. Europe's competitiveness should be enhanced through three 
main pillars for action: the resource base, networks and a pro-active role for public 
authorities. 
•  Reinforcing the resource base is of prime importance for this knowledge-
based industry; this calls first of all for enhancing life sciences education (life-
long learning for scientists, general awareness of the public). We also need 
training across disciplines and specialisation, including the potential for take-up of 
information and communication technologies in biotechnology; new ideas tend to 
emerge at the junction of specialisation. Scientific and engineering knowledge has 
to be matched with entrepreneurial management skills for successful company 
operation. This action pillar contributes directly to Europe's education
4 and 
employment
5 objectives. Comprehensive, up-to-date and publicly and freely 
available bioinformatics data is the basis for advances in biotechnology. In order 
                                                 
4  10 year-objectives in education and life-long learning 
5  Employment policy guidelines for 2002: improving employability; developing 
entrepreneurship and job creation; encouraging adaptability of businesses and their 
employees. 
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to flourish, companies need access to high quality public and private databases 
and tools. While maintaining strong public research, public support and 
intellectual property rules should encourage collaboration, especially 
public/private ones, that mobilise resources and support innovation. In the border 
region between research and application, the conditions for exploitation of 
knowledge, in particular well-managed risk capital and Europe-wide rules for 
intellectual property rights, make all the difference. The full implementation of 
Directive 98/44 on the legal protection of biotechnological inventions will 
considerably improve legal certainty for industry. The clarification of the 
legislative environment within the EC will provide innovative firms in the various 
industries using biotechnology with an incentive to continue or even increase their 
investments in research. In addition, the adoption of the Community patent would 
promote the competitiveness of the EC companies. 
•  We need to network Europe's Biotechnology Communities to facilitate open 
access to knowledge, skills and best practises, and to create a close community of 
actors and institutions involved in biotechnology. European-wide intellectual 
property protection must be completed to provide an affordable basis for 
technology transfer and co-operation. Links between the university and the 
industry spheres need to be strengthened. Research co-operation and technology 
transfer among regions and member states must be enhanced. There is a need to 
promote and facilitate different forms of networking and linking-up to overcome 
current fragmentation. Benchmarking allows the sharing of knowledge of good 
practices (e.g. on business clusters and incubators). An intelligent management of 
diversity may exploit the network benefits of regional clusters that are specialised 
in specific technologies. 
•  The fast development of biotechnology and the broad range of potential 
applications requires a pro-active role for public authorities to monitor the 
impact on competitiveness of the existing policy framework and to anticipate 
emerging issues and pro-actively adapt policies. This will need a pooling of the 
knowledge available to public decision-makers, through information exchange 
and networking. 
4. A  KEY ELEMENT FOR RESPONSIBLE POLICY:  GOVERNING LIFE SCIENCES 
AND BIOTECHNOLOGY 
The public debate on life sciences and biotechnology and the fundamental values 
affectedhighlight the need for responsible and coherent policies to govern these fast-
moving technologies. All key stakeholders have stressed the importance of 
governance, i.e. attention to the way public authorities prepare, decide, implement 
and explain policies and actions. 
The Commission proposes to apply the highest standards of governance of life 
sciences and biotechnology along 5 main action lines: 
•  Societal dialogue and scrutiny should accompany and guide the development of 
life sciences and biotechnology 
•  Life sciences and biotechnology should be developed in a responsible way in 
harmony with ethical values and societal goals 
The technology 
revolution calls 
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through ….  
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•  Informed choice should facilitate demand-driven applications 
•  Science-based regulatory oversight should enhance public confidence 
•  Basic regulatory principles and legal obligations should be respected to safeguard 
the Community single market and international obligations. 
4.1.  Societal scrutiny and dialogue 
Life sciences and biotechnology have given rise to significant public attention and 
debate. The Commission welcomes this public debate as a sign of civic responsibility 
and involvement. Life sciences and biotechnology should continue to be 
accompanied and guided by societal dialogue.  
Dialogue in our democratic societies should be inclusive, comprehensive, well 
informed and structured. Constructive dialogue requires mutual respect between 
participants, innovative approaches, and time. It should be structured in agreement 
with stakeholders to allow progress, for example in the provision of better 
information and mutual understanding. Experience also shows how important it is 
that dialogue takes place at the local and national levels, as well as internationally, 
and the Commission invites Member States and local actors to take relevant 
initiatives. 
Dialogue should be open for all stakeholders. Public authorities should help to 
ensure participation by stakeholders with limited resources.  Economic operators, 
industry and users, who have economic interests at stake, as well as the scientific 
community, bear a particular responsibility for active participation. The Commission 
invites these parties to respond to public concerns, for example through transparency 
of their visions, policies and ethical standards. 
Relevant public information  is essential for meaningful dialogue. Providing it 
requires focused and pro-active efforts. It is especially important that the information 
needs formulated by the broad public are taken seriously and responded to. We shall 
also strive for a balanced and rational approach, distinguishing between real issues, 
on which we must act, and false claims. 
4.2.  Developing life sciences and biotechnology in harmony with ethical 
values and societal goals 
Without broad public acceptance and support, the development and use of life 
sciences and biotechnology in Europe will be contentious, benefits will be delayed 
and competitiveness will be likely to suffer. 
The debate and the public consultation carried out by the Commission
6 indicate that 
the European public is quite prepared and capable to enter into complex weighting of 
benefits against disadvantages, guided by fundamental values. Although sometimes 
polarised, the public debate demonstrates many points of converging views. 
Public opinion depends crucially on the perceived benefits of life sciences and 
biotechnology. Eurobarometer surveys reveal that public expectations of 
                                                 
6  The Commission intends to publish these comments on the Internet 
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biotechnology, apart from medical advances, are moderate. And there is also 
considerable public uncertainty about some applications, and aversion towards their 
distributional impacts and the risks involved. 
There is broad support for many guiding values and goals. Some of these, such as the 
freedom of research, intrinsic value of new knowledge and the moral obligations to 
help alleviate illness or hunger, tend to favour the development and application of 
these new technologies. Others help to clarify the criteria and conditions for the 
development and applications of life sciences and biotechnology, in particular the 
need to take into account the ethical and societal implications, and the importance of 
transparency and accountability in decision-making, minimising risk, and freedom of 
choice. 
It is therefore of key importance to support information and dialogue to help the 
public and stakeholders better understand and appreciate these complex issues and to 
develop methods and criteria for assessing benefits against disadvantages or risks, 
including the distribution of impacts among different parts of society. 
Our democratic societies should offer the necessary safeguards to ensure that the 
development and application of life sciences and biotechnology take place respecting 
the fundamental values recognised by the EU in the Charter of Fundamental 
Rights, in particular by confirming the respect for human life and dignity. The 
Community has also banned funding of research into human reproductive cloning. 
Support should be given to the Frano-German initiative, addressed to the UN, for a 
world-wide convention on the prohibition of human reproductive cloning. Other 
issues such as stem cell research clearly require attention and further debate. Europe 
has also taken clear positions on the importance of freedom of choice for consumers 
as well as for economic operators with respect to GM foods, and we have established 
broad societal agreement on the need to safeguard European agricultural practices. 
However, scientific and technological progress will continue to give rise to new 
ethical or societal implications. The Commission considers that these issues should 
be addressed pro-actively and with a broad perspective, taking into account the moral 
obligations towards present and future generations and the rest of the world. We 
should not content ourselves with acting defensively only when our core values are 
being transgressed.  
These issues cannot be adequately addressed within the narrow context of regulatory 
product approvals but require more flexible and forward-looking approaches. Europe 
needs an active and on-going public dialogue, accompanied by focused fact-finding 
on both benefits and disadvantages to allow the public to contribute to the complex 
process of setting priorities. In the context of its Science & Society initiative
7, the 
Commission has already proposed a series of actions intended to strengthen the 
ethical dimension in sciences and new technologies. 
To be at the front of developments, Europe should have the capacity for 
foresight/prospective analysis and the necessary expertise to help clarify the often 
complex issues for policy makers and the public, and to place them in their scientific 
and socio-economic context. The Commission welcomes the key role played by the 
                                                 
7 COM(2001)714  of  4.12.2001  
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European Group on Ethics in Science and New Technologies since its creation in 
the early 1990s and proposes, as part of the present strategy, to enhance its role and 
to reinforce the networking with and between national ethical bodies. To this end, an 
additional targeted consultation of the other Community institutions is envisaged.  
Moreover, transparency, accountability and participatory approaches in public 
policy-making need to be reinforced. These objectives coincide with those of the 
Commission’s White Paper on European Governance
8 and will be pursued through 
the actions proposed therein. 
4.3.  Demand-driven applications through informed choice 
The regulatory oversight applied to the development and use of life sciences and 
biotechnology is the expression of societal choices. Regulation and other public 
policy measures set the rules and conditions, under which life sciences and 
biotechnology may be developed and applied. Regulation should therefore ensure 
that market mechanisms function effectively to obtain the stated objectives. This is 
the purpose of Europe’s policy of mandatory labelling which aims to ensure that 
consumer’s preferences are translated into incentives for producers to adapt supply.  
As far back as 1990 and after lengthy discussions, the Community opted for a 
science-based regulatory approach that subjects all commercial uses of genetically 
modified organisms to ex-ante public scrutiny and safety approval on a case-by-case 
basis, prior to any application, release into the environment or marketing. As a result 
of this approach, a revised framework legislation on GMOs has been adopted and 
will enter into force in October 2002. The new legislation provides a sound basis to 
overcome the present standstill in authorising new products. 
•  Under the Community's regulatory approach in sectors where pre-marketing 
authorisation is required, authorisation is granted after a scientific evaluation of 
the risks which the product may present for human and animal health or for the 
environment, taking into account other factors legitimate to the matter under 
consideration. In the logic of this approach, it is for the markets to determine 
whether products survive. But it is essential to ensure that the market mechanisms 
work effectively so that consumers can exercise choice and thus send clear 
signals to suppliers. Over the last 5 years, Europe has pioneered solutions to 
ensure informed consumer choice through labelling – these need urgently to be 
completed and put into application.  
•  In order to fully apply the principle of freedom of choice for economic 
operators and to safeguard sustainability and diversity of agriculture in Europe, 
public authorities in partnership with farmers and other private operators need to 
develop agronomical and other measures to facilitate the co-existence of different 
agricultural practices without excluding GM crops. 
4.4.  Confidence in science-based regulatory oversight 
Where safety is an issue, Community legislation is science-based and its application 
with respect to specific decisions will be in accordance with the precautionary 
                                                 
8  COM(2001)428 final of 25.7.2001 
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principle
9. The European Agency for Evaluation of Medicinal Products is a 
successful example of setting high standards of scientific advice and effective risk 
communication. With the creation of the European Food Safety Authority (EFSA), 
the already high standards of excellence, independence and transparency of scientific 
advice in that field will be taken further and new emphasis will be placed on risk 
communication. EFSA will be responsible for scientific assessments of 
environmental, human and animal health effects of GMOs and GM food and feed, 
and will have a forward-looking responsibility for identifying emerging risks, 
including those potentially arising from the application of biotechnology in agri-food 
production. These are essential contributions to public trust in the scientific basis for 
regulatory oversight for the safety of existing foods and medicines as well as new 
applications. Building public confidence and understanding must be a permanent 
concern.  
•  There is a general need to enhance public trust in the role of science in our 
societies. The Commission has proposed an action plan on Science & Society to 
promote scientific culture, to better take into account public needs in setting the 
scientific agenda, and to place science at the heart of European policies. Public 
authorities, economic operators and the scientific community should actively 
present relevant knowledge and facilitate understanding on key issues, including 
that scientific knowledge is always advancing and therefore regularly improves 
our reference points. Moreover, it is an essential part of the process of public 
understanding and policy formulation to also evaluate the risks of not taking 
action, for example against the evolution of new or drug-resistant diseases and in 
areas where current agricultural practices are unsustainable. 
•  Biotechnological inventions require high capital investment, long development 
cycles and comprehensive regulatory approval. Effective patent protection is a 
crucial incentive to R&D and innovation and an essential means of guaranteeing 
return on investment. Moreover, the disclosure of information in patent 
publication has been important in contributing to the overall development of 
biotechnology. In view of the rapid scientific progress, legislation on intellectual 
property needs to be monitored very closely. Regular assessments need to be 
made on whether the patent regime satisfies the needs of researchers and 
companies. In this respect, the EC and its Member States should ensure that the 
interpretation of the essential criteria of novelty, invention and utility in the field 
of life sciences is not left exclusively to courts and patent offices. As regards the 
international context, there is a need to work towards a level playing field in 
patent protection in industrialised countries. Steps need to be taken in view of 
promoting international dialogue on this issue. 
•  The basis for Community regulation of these new technologies should be more 
transparent and better communicated. For example, we should be clearer about 
how regulators deal with risk - potential risk, scientific uncertainty (e.g. the 
absence of zero-risk, the application of the precautionary principle), weighing of 
comparative risks, the role of the different stages of risk analysis, the role of risk 
management measures such as monitoring and safeguards, and their 
proportionality with risk. In addition, whilst underlining the importance of legal 
                                                 
9  Commission’s Communication on the Precautionary Principle COM (2000)1 final of 
2.2.2000, and the Nice European Concil conclusions  
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certainty and predictability, we need to stress the reversibility of regulatory 
decisions when justified and highlight the on-going work on international 
convergence of risk analysis methodologies and development of anticipatory risk 
analysis methodologies. Publicly funded research in support of regulatory 
oversight is of particular importance for public confidence. 
•  Specific initiatives proposed in the Commission's White Paper on European 
Governance are particularly relevant for enhancing public confidence, in 
particular the planned improvements for openness and accountability in risk 
governance and in use of expertise. 
•  Confidence in our regulatory oversight is a responsibility of public authorities but 
also requires the responsible participation of other stakeholders such as the 
biotechnology industry, other economic operators, the scientific community, 
NGOs and the media. 
4.5. Regulatory  principles 
Community regulation currently governs such diverse aspects such as the patenting 
of biotechnological inventions, the authorisation of pharmaceutical products, 
contained use of genetically modified microorganisms, and release and marketing of 
products consisting of or derived from GMOs, including foods, feeds and seeds. This 
regulatory framework has evolved gradually over the last 25 years, with major 
developments in recent years.  
In order to improve the coherence, transparency and efficiency of Community 
regulation, the Commission suggests that Community regulatory activity should 
respect the following principles: 
•  Risk governance and product authorisation: Products of biotechnology should, 
in accordance with the established regulatory principles and frameworks, be 
authorised on the basis of a comprehensive scientific risk assessment if found to 
be safe for human, animal or plant life and health and the environment. In cases 
where scientific evidence is insufficient, inconclusive or uncertain, and where 
possible risks are judged to be unacceptable, risk management measures should be 
based on the precautionary principle. Risk management should take into account 
the results of risk assessment and other factors legitimate to the matter under 
consideration in order to achieve the chosen level of protection.. Procedures for 
authorisation should be transparent, risk assessments should be published and 
made available for public comment as part of the authorisation procedures. 
Communication needs to be an integral part of risk assessment and risk 
management activity. 
•  Safeguarding the Internal Market: To secure the functioning of the Internal 
Market and legal certainty, Community legislation should be drafted and 
periodically reviewed to ensure coherence and efficiency, including with regard to 
its practical feasibility and enforceability. Implementation of and compliance with 
Community law should be carefully monitored, and any problem of compliance 
should be addressed and resolved among concerned parties according to existing 
procedures in a transparent and predictable manner. 
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•  Proportionality and consumer choice: Community regulatory requirements 
should be proportionate to the degree of identified risk and should conform with 
the Community's international obligations. As proposed by the Commission, 
Community legislation should facilitate consumer choice through ensuring that 
consumers/users are informed in cases where a food, feed or seed is genetically 
modified or derived from GMOs. 
•  Predictability, modernisation and impact assessment: The Commission should 
periodically publish a rolling regulatory work programme (see point 6 below) to 
improve predictability, transparency and quality of regulation. Regulation should 
continue to be regularly reviewed to be up-to-date with scientific and 
technological progress, for evaluation of impacts and for conformity with the 
present principles. 
5. EUROPE IN THE WORLD - RESPONDING TO GLOBAL CHALLENGES 
The revolution in life sciences and biotechnology is global. Research is 
fundamentally international - knowledge and experts circulate throughout the world. 
A growing number of countries are actively pursuing biotechnologies, and the 
resulting products and services will increasingly be traded on global markets, with a 
premium for first innovators. 
It is also clear that great diversity exists between countries and regions with respect 
to their capacities to develop, regulate and apply the new products and services. Even 
greater diversity may emerge with respect to the priorities and societal values that 
will shape the approaches and choices to developing and using these new 
technologies. 
European policies should not be developed in isolation. We need to embrace the 
wider international context which shapes both challenges and opportunities for 
Europe, and we must respond with responsible and proactive policies at the global 
level. A main objective must be to ensure that the EU maintains competitiveness vis-
à-vis major industrialised countries such as the US and Japan. Moreover, whatever 
policies Europe will decide regarding life sciences and biotechnology, they will have 
important international impacts, in particular for developing countries. The interests 
of these countries must also be taken into account. We must integrate the 
international dimension into all relevant policies, and we need to develop an 
international agenda, based on our fundamental values and long-term objectives, to 
actively promote balanced and responsible policies globally, in particular towards the 
developing world. 
5.1.  A European agenda for international collaboration 
International collaboration is required to manage the novel issues raised by life 
sciences and biotechnology and the diversity of capacities and policies in different 
countries and regions towards their applications. 
Trade in goods and services is already being affected due to divergent product 
approval rates. International trade friction may also emerge if countries and regions 
adopt divergent regulatory frameworks. There is a need for international dialogue on 
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regulatory issues to develop mutual understanding of basic principles and values 
underlying regulatory developments in different countries. 
The Community is committed to open, multilateral, and rules-based trading systems. 
We should therefore promote respect and implementation of existing international 
agreements. Given the particular issues raised by life sciences and biotechnology, the 
Community should promote solutions and dialogue at international level that: 
•  Ensure mutual supportiveness between relevant international agreements and 
in particular between the WTO agreements and the Biosafety Protocol. 
•  Support a coherent, comprehensive, effective, transparent and inclusive approach 
to biotechnology across the relevant international fora in order to avoid overlaps 
and make the best use of their respective expertise (including FAO, UNEP, CBD, 
WTO, WHO and UNCTAD
10). Europe should continue to play a full part, in 
particular in the OECD and the Codex Alimentarius, and notably its Ad Hoc 
Intergovernmental Task-Force on Biotechnology, to promote within these 
organisations the development and periodic review of harmonised guidelines with 
respect to the risk analysis, the labelling and the traceability of products derived 
from modern biotechnology. The role and efficiency of EU participation in 
international discussions should be enhanced, including through discussions with 
developed and developing countries. Dialogue should promote mutual 
understanding of concerns and objectives of different countries and regions, such 
as the EU/US Biotechnology Forum which delivered its final report in December 
2000
11. Early policy dialogue about forthcoming legislation may reduce the 
potential for international friction. 
5.2.  Europe’s responsibilities towards the developing world 
Life sciences and biotechnology hold the promise of meeting some of the 
fundamental needs for food and health facing the developing world. The UNDP, in 
its 2001 Human Development Report, highlights the potential of biotechnology for 
the developing world
12. Some emerging economies such as China, India and Mexico 
have already initiated ambitious national development programmes.  
Life sciences and biotechnology are not a panacea and will not resolve the 
distributional problems of the developing world – but they will be one of the 
important tools. New capacities should help developing countries reconcile yield 
increases, sustainable use of natural resources, economic efficiency and social 
acceptability. Potential applications must be adequately researched and assessed, 
taking full account of both the environmental safety issues and the needs expressed 
by the populations concerned to reduce poverty and strengthen food security and 
nutritional quality.  
As a major actor in life sciences and technologies, Europe has a particular 
responsibility to help the developing world deal with the risks, challenges and 
                                                 
10  Food and Agriculture Organisation, United Nations Environmental Programme, Convention 
on Biological Diversity, World Trade Organisation, World Health Organisation, United 
Nations Convention on Trade and Development 
11 http://europa.eu.int/comm/external_relations/us/biotech/biotech.htm 
12 http://www.undp.org/hdr2001/ 
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opportunities, and to facilitate the safe and orderly development of these 
technologies at the global level. Europe already holds an influential position in 
international deliberations on life sciences and biotechnology. This needs to be taken 
forward with responsible policies to achieve our strategic objectives and to allow the 
safe and efficient use of life sciences and biotechnology in developing countries. 
•  Europe should continue to promote protection of biodiversity and the 
implementation of the Biosafety Protocol for international trade in living modified 
organisms. Moreover, Europe should continue to support negotiated multilateral 
frameworks such as the Convention on Biological Diversity and the FAO 
International Undertaking on Plant Genetic Resources. These international 
instruments regulate access to genetic resources and the sharing of the benefits 
arising from their use, in view of providing compensation to the centres of origin 
of genetic resources and the holders of traditional knowledge used in 
biotechnological inventions. The EC should contribute to ensure that the benefits 
generated by biotechnological inventions, including intellectual property income, 
are properly shared with the providers of genetic resources or traditional 
knowledge. 
•  Europe should contribute to technical assistance, capacity-building and 
technology transfer to allow developing countries to participate in negotiating 
and implementing international agreements and standards, notably on risk 
governance, and to safely develop and apply these new technologies if they so 
wish. Europe should support local initiatives for dialogue on biotechnology 
among public and private stakeholders and civil society in partner countries. 
•  Europe should encourage equitable and balanced North-South partnerships and 
public research for demand-driven applications of life sciences and 
biotechnology. 
•  Domestic European policies with regard to life sciences and biotechnology are 
bound to have major impacts on developing countries. Whilst not compromising 
EU food safety requirements or consumer information policies, we should provide 
technical assistance and capacity building to ensure that our policies do not, 
unwittingly, prevent developing countries from harvesting desired benefits. In 
particular, we should guard against regulatory requirements that may be 
manageable only in the industrial world but are unachievable by developing 
countries, thereby either upsetting existing trade or effectively blocking 
developing countries from developing life sciences and biotechnology at their 
own wish and pace. 
6. IMPLEMENTATION AND COHERENCE ACROSS POLICIES,  SECTORS AND 
ACTORS 
Europe does not have a single policy for life sciences and biotechnology but a patch-
work of specific regulation, overlaid by many sectoral and horizontal policies at 
international, Community, Member State and local levels. If, with so many actors 
and policies involved, Europe is to successfully manage life sciences and 
biotechnology and reap the benefits for society, we should proceed on the basis of a 
shared vision for a co-operative approach and with effective implementing 
mechanisms to compensate for absence of overall responsibility and control. Without 
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such mechanisms, life sciences and biotechnology risk to continue to suffer 
indecision or short-sighted and local solutions. 
The Commission proposes to structure and support implementation of the present 
strategy and the enclosed action plan through the following measures: 
•  To monitor progress in policy development and on the ground, and to anticipate 
emerging issues in this fast-developing area, the Commission will, starting in 
2002 and ending in 2010, present a regular Life Science and Biotechnology 
Report, including a rolling work programme for legislation. 
•  We need to ensure coherence across Community legislation and policies 
directly regulating, or indirectly impacting on, the development and application of 
life sciences and biotechnology. The Commission will, as part of its Life Science 
and Biotechnology Reports, review the coherence of Community policies and 
legislation affecting life sciences and biotechnology and launch initiatives and 
proposals as appropriate. Particular attention will be given to ensure that 
regulation on life sciences and biotechnology adequately integrates our 
international objectives and facilitates innovation and international 
competitiveness, that Community research contributes coherently and effectively 
to Community objectives, and that other Community policies and objectives (e.g. 
in environment, public health and consumer protection, education, employment, 
agriculture, trade and development policies) adequately reflect the long-term and 
global importance of life sciences and biotechnology. The Commission will 
evaluate whether existing international fora and bilateral dialogues are sufficiently 
effective and provide adequate flow of information, and whether the domestic 
coordination mechanisms can be improved. 
•  Where different levels of competence apply, the strategy should be a reference 
for collaboration between different actors (Community, national and local public 
authorities, economic operators, the scientific community etc). As part of the 
Lisbon strategy, coherent action for life sciences and biotechnology should be 
pursued through the established methods of coordination and benchmarking. In 
addition, new forms of collaboration and partnerships between stakeholders 
should be encouraged. Together with Member States, the Commission will also 
assess whether current patterns of competence and mechanisms of co-operation 
allow the effective achievement of the strategic objectives, incl. reassess whether 
there is a need for reinforcing Community competence in accordance with the 
Treaty. 
•  The Commission invites all institutions and public actors to strive for better 
coherence in their action. For its own part, it will seek to provide the vigilance 
and political impetus to keep momentum in implementing the present strategy, 
through its own action or through recommendations and invitations to other 
parties. The Commission intends to hold more regular orientation debates, 
coinciding with the adoption of the above mentioned Commission Life Science 
and Biotechnology Report.  
•  In order to facilitate transparency and structured dialogue on the further 
development and implementation of the proposed strategy for life sciences and 
biotechnology, the Commission will organise a broadly based Stakeholders’ 
Forum, including representatives of the candidate countries and third countries.  
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7. A  FRAMEWORK FOR DIALOGUE AND ACTION 
It is time to clarify the strategic opportunities and challenges facing Europe. Life 
sciences and biotechnology are a global reality and essential for the objective of 
developing dynamic and innovative knowledge-based economies. We have to face 
the difficult questions and identify our strategic objectives to avoid the pitfalls of 
short-term solutions to long-term challenges and of local solutions to global 
challenges. 
Recognising that life sciences and biotechnology raise particular challenges, the 
Commission undertook to propose a strategy and concrete actions. It now presents 
this initiative for a coherent, collaborative and sustained effort. 
The present initiative draws on a thorough analysis
13 of the strengths and weaknesses 
of European biotechnology, and a broad public debate and the specific public 
consultation launched by the Commission in September 2001. The initiative should, 
in turn, itself inspire further dialogue. The attached action plan suggests a broad 
scope of measures according to the orientations set out in chapters 3 to 6 of this 
Communication. It constitutes a framework, within which some actions can be 
launched in the short-term while other actions for the medium and longer term are 
identified and suggested for further development in collaboration with Member 
States and stakeholders. 
The Commission now invites the Community institutions and bodies, the Member 
States, protagonists and the public to contribute to refine and implement the proposed 
strategy by defining detailed measures under both short- and medium-term actions 
and the time-plan for their deliverables, as a first decisive step towards an effective 
and coherent European biotechnology policy.   
 
* * 
                                                 
13  European Competitiveness Report 2001, Luxembourg 2001; "Innovation and Competitiveness in 
European biotechnology", Enterprise Papers - N° 7, 2002, European Commission 
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Life sciences and biotechnology – A strategy for Europe 
PART II: ACTION PLAN 
1. HARVESTING  THE  POTENTIAL 
THE RESOURCE BASE 
Investing in People 
Action 1 
The Commission will together with competent authorities in Member States
1 identify the 
education needs in life sciences within the 10-year Objectives for Learning in the Knowledge 
Society
2 and: 
a)  strengthen a broad education and understanding of life sciences,  
b)  develop and train a skilled workforce in life sciences, 
by issuing recommendations for curricula and teacher training. Community support can be 
provided under the Comenius and Erasmus programmes. 
c)  As set out in its Communication on the European area of Lifelong learning
3, the 
Commission will work with Member States, industry, academia and others to identify 
measures to promote continuing education and refresh the current competence of the 
scientific workforce. Community support can be provided under the Leonardo 
programme. 
d)  The Commission and Member States should support discussion fora for specialist 
scientists, with the objective of stimulating an exchange across disciplines. Vital 
discoveries frequently happen at the point where disciplines intersect. Community 
support can be provided under the Erasmus programme. 
Implementer: Member States, Commission, private sector 
Timeframe: 2003-2010 
 
                                                 
1 Where reference is being made to the Member States in the action plan, the Commission will 
examine with interested candidate countries their participation. 
2 Education Council Report to the European Council 5980/01 
3 COM(2001) 678  
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Action 2 
The Commission will explore with Member States  
a)  the opportunity and best way to establish efficient methods to match a skilled 
workforce with job opportunities, involving effective communication of open 
positions, collaboration with established companies and a labour force aware of 
available employment options. 
b) possible  measures  to  attract and retain scientists and avoid brain drain. In achieving 
this, specific reference will be paid to the initiatives launched under the 
Communication «  A Mobility Strategy for the Research Area”
4, which aims at 
improving the overall environment of researchers and their families in the EU. Due 
attention will also be paid to the increased mobility opportunities offered by the 
forthcoming Sixth Framework Programme (2002-2006), and more particularly to the 
measures aimed at attracting foreign researchers and supporting the return of EU 
researchers established in other parts of the world. 
Implementer: Member States, Commission 
Timeframe: 2003 onwards 
 
                                                 
4 COM(2001)331final, of 20 June 2001,as supplemented by the Council’s Resolution of 20 December 
2001 concerning «  The Reinforcement of the Mobility Strategy within the European Research 
Area ».   
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Generating and exploiting knowledge 
Research 
Action 3 
The Commission will enhance its support for life sciences and biotechnology research, 
technological development, demonstration and training activities under the next 
Framework Programme 2002-2006 aimed at contributing towards the creation of the 
European Research Area. 
Biotechnology research will be supported under the thematic priorities, including:  
  1: Genomics and biotechnology for health   
 3:  Nanotechnologies 
  5: Food quality and safety 
 6:  Sustainable  development 
 7:  Citizens  and  governance 
Specific measures will be provided to encourage SME participation, international cooperation 
and mobility and training of researchers.  
The new instruments of Networks of Excellence and Integrated Projects will facilitate the 
objectives of Europe-wide collaborations, attaining critical mass and simplification of 
administrative procedures.  
The Commission and the Member States should also in collaboration with the European 
Investment Fund (EIF) develop a competitive bioinformatics infrastructure in support of 
biotechnology research and focus support for the development of research in computational 
biology and bio-medical informatics. 
Implementer: Member States, EIF, Commission 
Timeframe: 2002-2006 
Management and legal services 
Action 4 
Enhancing the supply of specific management and legal skills: 
a)  Member States and national biotechnology associations should examine the 
opportunity of creating self-sustained networks of biotechnology company 
managers at the national level. 
b)  Member States and the Commission should promote collaboration between law 
schools, law firms and companies for the development of specific legal competence 
needed by biotechnology companies. 
Implementer: Member States, academia, professional associations, Commission 
Timeframe: 2003 onwards  
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Exploitation of intellectual property 
Action 5 
A strong, harmonised and affordable European intellectual property protection system, 
functioning as an incentive to R&D and innovation will be finalised by: 
a)  Member States urgently transposing into national laws the Directive on the Legal 
Protection of Biotechnological Inventions EC/98/44. 
b)  Council adopting the Community Patent Regulation. 
c)  Member States and the Commission clarifying rules on ownership of intellectual 
property stemming from public research and monitoring the effect of implementation 
of patent legislation on research and innovation. 
d)  encouraging awareness training in the strategic use of IPR during the entire research 
and innovation process and raising awareness among academics of the commercial 
potential of their research, encouraging entrepreneurship and movement between 
academia and companies. 
e)  taking steps to promote international dialogue and co-operation with a view to work 
towards a level playing field with industrialised countries in patent protection on 
biotechnology inventions, ensuring an effective level of protection for innovation in 
this field. 
Implementer: Member States, Council, Commission 
Timeframe: 2002 onward 
 
Capital base 
Action 6 
The Commission should together with the European Investment Bank (EIB) and the European 
Investment fund (EIF) strengthen the capital base for the biotechnology industry, by: 
a)  seeking to stimulate investments in research and technological innovation via 
complementary financing on the basis of the co-operation agreement signed in 
June 2001 between the Commission and the EIB group. 
b)  seeking to stimulate investments in business incubators through the EIF Start Up 
Facility 
c)  studying measures to support technology transfer mechanisms, such as financing of 
patent pools or other methods for patent exploitation. 
d)  studying measures to encourage commercial financing of companies based on a 
medium-term investment perspective. 
Implementer: EIB Group, Commission 
Timeframe: 2002 onwards  
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Action 7 
The Commission will strengthen the work of the Biotechnology and Finance Forum by the 
inclusion of relevant major stakeholders to provide advice into policy development in the 
field of capital supply.  
Implementer: Commission 
Timeframe: 2002 
 
NETWORKING EUROPE’S BIOTECHNOLOGY COMMUNITIES 
Networks in Europe 
Action 8 
The Commission will:  
a) support  creation  of  a commercial biotechnology web portal for Europe that will 
help free access to information and networking available Internet platforms. The 
contents of such a portal will have to be defined based on the requirement of economic 
viability and sustained demand.  
b)  develop its newly created Commission web site to provide a broad entry platform 
into the Commission’s work on biotechnology. 
Implementer: Commission 
Timeframe: 2002-2003 
Action 9 
Member States, their regions, the Commission and EIB should support: 
a)  stronger interregional co-operation, e.g. through a network of biotechnology 
regions. Crossborder and interregional co-operation can receive funding from the 
Interreg programmes (notably Interreg IIIB and IIIC). 
b)  networks of biotechnology clusters. In addition, the Commission will organise a 
European competition between Biotechnology Innovation clusters, to highlight their 
capability to develop a cluster with a focus of excellence in a specific scientific field. 
Implementer: Member States, Regions, EIB, Commission 
Timeframe: 2003-2006 
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A PROACTIVE ROLE FOR PUBLIC AUTHORITIES 
Action 10 
The Commission will establish  
a) a  competitiveness monitoring function and a contact network with Member 
States ministries with responsibility for competitiveness in biotechnology. 
Monitoring should include impact on European competitiveness of legislation and 
policy measures.  
b) a  Competitiveness in Biotechnology advisory group with industry and academia to 
assist in identification of issues affecting European competitiveness. The Group will 
provide input into the Commission’s regular reports on Life Sciences and 
Biotechnology. 
Implementer: Member States, Commission 
Timeframe: 2002 
Action 11 
Transparency in the administrative process: 
a)  The Commission and Member States ,as regulatory authorities, should aid applicants, 
especially from start-up companies and SME’s, requesting approval through the 
regulatory process.  
b)  The Commission will issue a guide to Community regulation for users and for 
entrepreneurs who have limited staff and expertise in the regulatory and legal fields. 
Such a guide should also benefit non-EU (e.g. developing world) applicants and the 
general public. 
Implementer: a) Member States, Commission. b) Commission 
Timeframe: 2003 onwards 
 
Action 12 
In collaboration with the involved actors, the Commission will benchmark good practices in 
clustering biotech companies and in the work of business incubators and disseminate 
results. The Commission will also establish with Member States a programme for 
benchmarking relevant elements of biotechnology policies, in addition to existing 
benchmarking structures.  
Implementer: Commission 
Timeframe: 2003 onwards  
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2. A  KEY ELEMENT FOR RESPONSIBLE POLICY:  GOVERNING LIFE SCIENCES 
AND BIOTECHNOLOGY 
SOCIETAL SCRUTINY AND DIALOGUE 
Action 13 
The Commission, Member States, organisations, institutions and other actors should engage 
in a structured dialogue at various levels to develop an understanding and information 
exchange on life sciences and biotechnology. The Commission will in particular help 
mobilise all key actors in the public debate and facilitate participation of stakeholders with 
limited resources.  
In particular: 
a)  The Commission will propose a framework for a process of dialogue and follow-up 
with stakeholders as a result of the European strategy for life sciences and 
biotechnology. The framework will notably include a broadly based Stakeholders’ 
Forum. In this process, the Commission will take the initiative to better explain 
Europe’s regulatory approach (including the application of the precautionary principle, 
the role of risk management, monitoring, safeguards and reversibility of regulatory 
decisions).  
b)  The Commission will take initiatives, and invites the scientific community and other 
stakeholders to assist, to promote awareness of key scientific paradigms 
underlying regulatory oversight such as scientific uncertainty, absence of zero 
risk, comparative risks, that science is continuously evolving and therefore 
continuously improves our reference points, and the articulation between the steps in 
the risk analysis process. Within their respective fields, the European Food Safety 
Authority and the European Agency for the Evaluation of Medicinal Products will 
play an important role in general risk communication, including the scientific 
background for their conclusions of risk assessments.  
c)  Beyond these two specific initiatives, the Commission will also encourage public 
debates on biotechnology between scientists, industry and civil society, including 
specific interest groups, such as patients groups, farmers and consumers, focussing on 
specific technological developments, to raise public interest in such developments and 
offer early information on potential benefits and risks. Developers in the scientific 
community and in industry have a specific responsibility in actively explaining the 
background and the benefits of their products. 
Implementer: Member States, Industry, Academia, Civil society, EFSA, EMEA, 
Commission 
Timeframe: 2002 onwards 
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DEVELOPING LIFE SCIENCES AND BIOTECHNOLOGY IN HARMONY WITH ETHICAL 
VALUES AND SOCIETAL GOALS 
Action 14 
The Commission will strengthen and focus Community support for research into socio-
economic and ethical issues and dissemination of results, including criteria for assessing the 
benefits of using biotechnology in agri-food production, to facilitate future reporting and to 
provide a good basis for societal decisions on the application of biotechnology and life 
sciences. The Commission will program research support to a more systematic mapping of 
benefits and disadvantages/risks which should include a strong component for dissemination 
of information and debate. 
The Commission will ensure that ethical, legal and social implications are taken into 
account at the earliest possible stages of Community supported research by means of 
funding bioethics research and of providing an ethical review of research proposals 
received.  
Implementer: Commission 
Timeframe: 2002-2006 
 
Action 15 
The Commission proposes to enhance the role of the European Group on Ethics. In 
addition, the Commission will launch a separate consultation of the other Community 
institutions on possible structural and procedural improvements. The Commission will also 
promote collaboration between Community, national and local levels by promoting 
networking of national and local ethical bodies and elected representatives. The 
Commission will organise a network of academic and professional experts for ad-hoc 
advice on specific socio-economic aspects. 
Implementer: Ethical bodies, Legislatures, Commission  
Timeframe: 2002 
 
Action 16 
The Commission will develop, jointly with the EP, outreach measures to inform about 
the analysis of ethical issues at the EU level.  
While respecting cultural pluralism, the Commission will work with public and private 
partners to identify areas where it is possible to establish consensus on ethical 
guidelines/standards or best practise. Areas might include stem cell research, biobanks, 
xenotransplantation, genetic testing and use of animals in research. Such guidelines could, 
when appropriate, take the form of self-regulatory initiatives in the scientific community and 
industry. 
Implementer: European Parliament, Member States, Regions, Industry, Institutions, 
Commission 
Timeframe: 2002 onwards 
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DEMAND-DRIVEN APPLICATIONS THROUGH INFORMED CHOICE 
Action 17 
The Commission will take initiative to develop, in partnership with Member States, farmers 
and other private operators, research and pilot projects to clarify the need, and possible 
options, for agronomic and other measures to ensure the viability of conventional and 
organic farming and their sustainable co-existence with genetically modified crops. 
Moreover, the Commission recognises the importance of safeguarding the existing genetic 
resources in agriculture. It will launch a new action programme for the conservation, 
characterisation, collection and utilisation of genetic resources in agriculture in the 
Community. 
Implementer: Member States, professional associations, other operators, Commission 
Timeframe: 2002 onwards 
 
CONFIDENCE IN SCIENCE-BASED REGULATORY OVERSIGHT 
Pharmaceutical legislation 
Action 18 
Parliament and Council are invited to speed up the adoption of the three legislative proposals, 
revising the Community pharmaceutical legislation, including measures: 
a) to  develop and reinforce the system of giving scientific advice and to increase the 
access of the European Agency for Evaluation of Medicinal Products’ (EMEA) 
scientific committees to high level expertise through the creation of expert panels 
and permanent working groups. The increased level of expertise will also help the 
revision and development of European guidelines on the quality, safety and efficacy 
aspects of biotechnological medicinal products. 
b)  to introduce an accelerated procedure for products with a major public health 
interest that will allow the assessment and authorisation of a medicinal product 
within a shortened time scale 
c) to  introduce  a procedure allowing a conditional authorisation valid for one year, 
but renewable. This will allow products of major public health interest but for which 
certain studies are still in progress to be given a conditional access to the market 
during the finalisation of the studies. 
Implementer: European Parliament, Council 
Timeframe: 2002 
  
 31    
Genetically modified organisms (GMO) legislation 
Short-term regulatory actions 
Action 19 
Parliament and Council are invited to speed up the adoption of the two following legislative 
proposals: 
a)  Proposal for a European Parliament and Council Regulation on Traceability and 
Labelling of Genetically Modified Organisms and Traceability of Food and 
Feed derives from Genetically Modified Organisms. 
b)  Proposal for a European Parliament and Council Regulation on Genetically 
Modified Food and Feed. 
Implementer: European Parliament, Council 
Timeframe: 2002 
 
 
Action 20 
The Commission continues its work with a view to finalising the legislative proposals which 
have already been announced, such as initiatives concerning GM plant propagating material, 
environmental liability and the implementation of the biosafety protocol.  
Implementer: European Parliament, Council, Commission 
Timeframe: 2002-2003 
 
Implementation and enforcement activities 
Action 21 
The Commission will ensure that legislation is enforced in a uniform and effective way 
across the Community and adopt appropriate implementing measures required under 
relevant legislation, including the necessary guidance for detection and sampling 
methodology. The Commission will also establish a molecular register that is accessible to 
the public, containing information on events of genetic modification. 
Implementer: Commission 
Timeframe: 2002-2003 
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Specific long term regulatory actions 
Action 22 
The Commission will report on the feasibility of options to improve further the consistency 
and efficiency of the framework for authorising GMO’s for deliberate release into the 
environment, including a centralised Community authorisation procedure. 
Implementer: Commission 
Timeframe: 2003 
 
Action 23 
The Commission will support the development of methodologies for monitoring potential 
long-term environmental impacts of GMO’s as compared with conventional crops, and 
methodologies for the monitoring of effects of genetically modified food and feed as 
compared with conventional food and feed. With the establishment of the European Food 
Safety Authority, the work on the early identification of emerging risks will be reinforced and 
upgraded. 
Implementer: Commission 
Timeframe: 2002 onwards 
 
3.  EUROPE IN THE WORLD - RESPONDING TO GLOBAL 
CHALLENGES 
A EUROPEAN AGENDA FOR INTERNATIONAL COLLABORATION 
Action 24 
The Commission should continue to play a leading role in developing international 
guidelines, standards and recommendations in relevant sectors, based on international 
scientific consensus and, in particular, push for the development of a consistent, science-
based, focused, transparent, inclusive and integrated international system dealing with food 
safety issues. 
Implementer: Commission 
Timeframe: 2002 onwards 
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EUROPE’S RESPONSIBILITIES TOWARDS THE DEVELOPING WORLD 
Agriculture 
Action 25 
The Commission will in co-operation with Member States support: 
a)  the redefining of national research towards an appropriate mix of traditional 
techniques and new technologies, based on priorities developed with local farmers.  
b)  the establishment of effective research partnerships between public and private 
research organisations in developing countries and in the EU, and the adequate 
capacity and infrastructure for developing countries to enter into such 
partnerships, in accordance with international commitments under the Conventions. 
c)  sub-regional, regional and international organisations, in particular the 
International Agricultural Research Centres. 
Implementer: Member States, Commission 
Timeframe: 2002 onwards 
 
Genetic resources 
Action 26 
The Commission and the Member States will support the conservation and sustainable use 
of genetic resources in developing countries and their equitable sharing of benefits arising 
from their use by: 
a)  supporting the development and enforcement of effective measures to conserve, to 
use sustainably and to provide access to genetic resources and traditional 
knowledge, as well as to share equitably the benefit arising from them, including 
income generated by intellectual property protection. Support for local communities is 
vital to conserve indigenous knowledge and genetic resources. 
b) supporting  the  participation of delegates from developing countries in the 
negotiations of relevant International Conventions.  
c)  supporting measures to promote greater regional co-ordination in legislation to 
minimise disparities in access, benefits and also trade in products derived from genetic 
resources, in accordance with international commitments.  
Implementer: Member States, Commission 
Timeframe: 2002 onwards 
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Health 
Action 27 
The Commission and the Member States should work with the international community to 
concretise the commitment to research to combat HIV/AIDS, Malaria, TB and other 
main poverty-related diseases and also identify effective measures to support developing 
countries in establishing the structures needed to deploy a health policy. 
Implementer: Member States, Commission 
Timeframe: 2002 onwards 
 
Responsible and careful use 
Action 28 
The Commission should support: 
a) the  safe and effective use of modern biotechnologies in developing countries, 
based on their autonomous choice and on their national development strategies. 
b)  measures to increase the capacity of developing countries to assess and manage 
risk for man and the environment, under conditions prevailing in the country. 
c)  the development of appropriate administrative, legislative and regulatory measures in 
the developing countries, for the proper implementation of the Cartagena 
Protocol. 
d)  that international research on social, economical and environmental impacts are 
effectively adapted to take into account conditions prevailing in developing countries 
and that the findings are subsequently disseminated to them in an appropriate format.
e)  that the international regulatory requirements remain manageable by developing 
countries, so as not to impede their trade and production prospects. 
Implementer: Commission 
Timeframe: 2002 onwards 
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4.  IMPLEMENTATION AND COHERENCE ACROSS POLICIES, 
SECTORS AND ACTORS 
Action 29 
The Commission will enhance 
a) the  general  foresight function across Commission services, and in particular its role 
in technology foresight through its Institute for Prospective Technological Studies 
(IPTS), for early identification of newly emerging issues and of elements of a policy 
response  
b) its  monitoring and review function to assess 
-  the relevance, coherence and effectiveness of legislation and policy  
-  the extent to which policy objectives are achieved and legislation 
enforced 
-  the societal and economic impact of legislation and policy measures. 
In pursuit of these objectives and to further strengthen policy coherence, the Commission  
c)  will reinforce continuous co-ordination between its services and calls upon Member 
States to also provide enhanced foresight/review functions and a co-ordinated interface 
for a dialogue on these issues. 
Implementer: Commission, Member States  
Timeframe: From 2002 onwards 
 
Action 30 
The Commission will present a regular Report on Life Sciences and Biotechnology to 
monitor progress and indicate possible specific proposals to ensure policy and legislative 
coherence. The report will draw on the conclusions under actions 11 and 30. 
Implementer: Commission 
Timeframe: 2003 onwards 
 